Cargando…

Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China

BACKGROUND: To compare the overall survival (OS) of patients with advanced lung adenocarcinoma in China before and after the approved use of gefitinib, and analyze clinical factors that may affect OS. METHODS: Clinical data of 558 patients with advanced lung adenocarcinoma who received chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yu-Tao, Hao, Xue-Zhi, Li, Jun-Ling, Hu, Xing-Sheng, Wang, Yan, Wang, Zi-Ping, Wang, Hong-Yu, Wang, Bin, Han, Xiao-Hong, Zhang, Xiang-Ru, Shi, Yuan-Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567010/ https://www.ncbi.nlm.nih.gov/pubmed/26445613 http://dx.doi.org/10.1111/1759-7714.12267

Ejemplares similares

Gefitinib improves severe bronchorrhea and prolongs the survival of a patient with lung invasive mucinous adenocarcinoma: A case report
por: Ou, Guo-Chun, et al.
Publicado: (2023)

Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
por: Li, Ya‐Qing, et al.
Publicado: (2017)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis
por: Wang, ZheXing, et al.
Publicado: (2018)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells
por: Hu, Chun-Sheng, et al.
Publicado: (2021)

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
por: Liu, Chien-Ming, et al.
Publicado: (2015)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
por: He, Jian, et al.
Publicado: (2023)

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro
por: Zhuang, Hong-Qing, et al.
Publicado: (2009)

Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients
por: Zou, Junyong, et al.
Publicado: (2022)

Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China
por: Qiu, Miao-zhen, et al.
Publicado: (2013)

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network
por: Wang, Qi, et al.
Publicado: (2022)

Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report
por: Kok, Victor C., et al.
Publicado: (2021)

FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop
por: Wang, Yu, et al.
Publicado: (2016)

GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma
por: Wei, Xing, et al.
Publicado: (2018)

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
por: Xu, Wei, et al.
Publicado: (2015)

Knowledge, attitudes, and influencing factors of cancer patients toward approving advance directives in China
por: Zheng, Ru-jun, et al.
Publicado: (2016)

MiRNA-125a-5p: a regulator and predictor of gefitinib’s effect on nasopharyngeal carcinoma
por: Liu, Yanyang, et al.
Publicado: (2014)

Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures
por: Nishimura, Tsutomu, et al.
Publicado: (2006)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

Golgi phosphoprotein 3 sensitizes the tumour suppression effect of gefitinib on gliomas
por: Wang, Xu, et al.
Publicado: (2019)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment
por: Xue, Cong, et al.
Publicado: (2015)

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
por: WANG, YUE FENG, et al.
Publicado: (2014)

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
por: Liu, Zhe, et al.
Publicado: (2021)

Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma
por: Lee, Joo Young, et al.
Publicado: (2012)

Orbital metastasis secondary to pulmonary adenocarcinoma treated with gefitinib: a case report
por: Koma, Yasuko, et al.
Publicado: (2012)

Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
por: Maeda, Ai, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hmel76t1jamin1t7ajk0758la3